Skip to content

Journal Highlights: stability of anticancer drugs

On 10 May 2012, the European Journal of Hospital Pharmacy published a multi-authored research article in relation to stability studies of anticancer drugs.

The starting point of the article is that stability studies performed by the pharmaceutical industry are only designed to fulfil licensing requirements. This can lead to a need for additional stability data covering practical uses of anticancer drugs e.g. post-dilution or reconstitution stability data.

A European consensus conference was held in France in May 2010, under the auspices of the French Society of Oncology Pharmacy (SFPO), to propose adapted rules on stability in practical situations and guidelines for performing corresponding stability studies.

The considerations and recommendations arising from that conference are then explored in full in the Journal article.

Article here

×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.